# NCT06215118 (NCT06215118)

> A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06215118
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Multiple Myeloma
- Interventions: Elranatamab; Iberdomide
- Enrollment: 100
- Primary outcome: Part 1: Number of participants with dose limiting toxicity (DLT)
- Primary outcome: Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment

## Commentary we found

- YouTube: 11
- X threads: 5
- Podcasts: 1
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct06215118

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06215118", "email": "<work email>"}; the inbox owner confirms by the emailed link.